Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
- PMID: 31264002
- PMCID: PMC6689028
- DOI: 10.1007/s10557-019-06887-9
Effects of PDE-5 Inhibition on the Cardiopulmonary System After 2 or 4 Weeks of Chronic Hypoxia
Abstract
Purpose: In pulmonary hypertension (PH), hypoxia represents both an outcome and a cause of exacerbation. We addressed the question whether hypoxia adaptation might affect the mechanisms underlying PH alleviation through phosphodiesterase-5 (PDE5) inhibition.
Methods: Eight-week-old male Sprague-Dawley rats were divided into two groups depending on treatment (placebo or sildenafil, a drug inhibiting PDE5) and were exposed to hypoxia (10% O2) for 0 (t0, n = 9/10), 2 (t2, n = 5/5) or 4 (t4, n = 5/5) weeks. The rats were treated (0.3 mL i.p.) with either saline or sildenafil (1.4 mg/Kg per day).
Results: Two-week hypoxia changed the body weight (- 31% vs. - 27%, respectively, P = NS), blood hemoglobin (+ 25% vs. + 27%, P = NS) and nitrates+nitrites (+ 175% vs. + 261%, P = 0.007), right ventricle fibrosis (+ 814% vs. + 317%, P < 0.0001), right ventricle hypertrophy (+ 84% vs. + 49%, P = 0.007) and systolic pressure (+ 108% vs. + 41%, P = 0.001), pulmonary vessel density (+ 61% vs. + 46%, P = NS), and the frequency of small (< 50 µm wall thickness) vessels (+ 35% vs. + 13%, P = 0.0001). Most of these changes were maintained for 4-week hypoxia, except blood hemoglobin and right ventricle hypertrophy that continued increasing (+ 52% vs. + 42%, P = NS; and + 104% vs. + 83%, P = 0.04). To further assess these observations, small vessel frequency was found to be linearly related with the right ventricle-developed pressure independent of hypoxia duration.
Conclusions: Thus, although hypoxia adaptation is not yet accomplished after 4 weeks, PH alleviation by PDE5 inhibition might nevertheless provide an efficient strategy for the management of this disease.
Keywords: Adaptation; Chronic hypoxia; Phosphodiesterase-5 inhibition; Pulmonary angiogenesis; Right-ventricle hypertrophy.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures






Similar articles
-
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.Circulation. 2003 Jul 1;107(25):3230-5. doi: 10.1161/01.CIR.0000074226.20466.B1. Epub 2003 Jun 9. Circulation. 2003. PMID: 12796132
-
Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8. Cardiovasc Res. 2009. PMID: 19131365
-
Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.PLoS One. 2015 Jan 28;10(1):e0117211. doi: 10.1371/journal.pone.0117211. eCollection 2015. PLoS One. 2015. PMID: 25629315 Free PMC article.
-
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.Circulation. 2003 Jan 21;107(2):234-7. doi: 10.1161/01.cir.0000050653.10758.6b. Circulation. 2003. PMID: 12538421
-
Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.PLoS One. 2018 Apr 20;13(4):e0195047. doi: 10.1371/journal.pone.0195047. eCollection 2018. PLoS One. 2018. PMID: 29677206 Free PMC article.
Cited by
-
Nitric Oxide-cGMP Pathway Modulation in an Experimental Model of Hypoxic Pulmonary Hypertension.J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):665-676. doi: 10.1177/10742484211014162. Epub 2021 May 8. J Cardiovasc Pharmacol Ther. 2021. PMID: 33969747 Free PMC article.
-
COVID-19-associated cardiovascular morbidity in older adults: a position paper from the Italian Society of Cardiovascular Researches.Geroscience. 2020 Aug;42(4):1021-1049. doi: 10.1007/s11357-020-00198-w. Epub 2020 May 20. Geroscience. 2020. PMID: 32430627 Free PMC article. Review.
-
Sildenafil reverses the hypertrophy of mice right ventricle caused by hypoxia but does not reverse the changes in the myosin heavy chain isoforms.Int J Physiol Pathophysiol Pharmacol. 2020 Jun 15;12(3):79-87. eCollection 2020. Int J Physiol Pathophysiol Pharmacol. 2020. PMID: 32714496 Free PMC article.
-
Inhibition of Sodium/Hydrogen Exchanger-1 in the Right Ventricle and Lung Dysfunction Induced by Experimental Pulmonary Arterial Hypertension in Rats.J Am Heart Assoc. 2025 Mar 18;14(6):e036859. doi: 10.1161/JAHA.124.036859. Epub 2025 Mar 7. J Am Heart Assoc. 2025. PMID: 40055146 Free PMC article.
-
Study of the Effect of Treatment With Atrial Natriuretic Peptide (ANP) and Cinaciguat in Chronic Hypoxic Neonatal Lambs on Residual Strain and Microstructure of the Arteries.Front Bioeng Biotechnol. 2020 Nov 10;8:590488. doi: 10.3389/fbioe.2020.590488. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33244466 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous